BioSpace News Archive

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the 17th Annual Wells Fargo Securities Healthcare Conference.

The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 18, 2022, approved the fiscal year 2023 second quarter cash dividend of $0.68 per ordinary share, representing an 8% increase over the prior year.

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 365,800 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Kodiak Sciences Inc. (Nasdaq: KOD), today announced that results from the Phase 3 BEACON study in Retinal Vein Occlusion (RVO) of its investigational therapy tarcocimab tedromer (KSI-301) will be presented at two upcoming ophthalmology conferences: the 22nd EURETINA Congress in Hamburg, Germany, and the 2022 American Academy of Ophthalmology Meeting in Chicago, Illinois.

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), today announced that data from the core period of the pivotal Phase 3 ACTIVATE-T study of PYRUKYND® (mitapivat) in adults with pyruvate kinase (PK) deficiency who receive regular transfusions were published on August 18, 2022, in The Lancet Haematology.

Accelerate Diagnostics, Inc. announced the pricing of an underwritten public offering of 17,500,000 shares of its common stock at a price to the public of $2.00 per share.

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported its half-year and second quarter financial results for the periods ended June 30, 2022 and provided a corporate update.

Astellas Pharma Inc. announced that the U.S. Food and Drug Administration has accepted the company’s New Drug Application for fezolinetant, an investigational oral, nonhormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms associated with menopause.

The Company’s revenue increased 113.7% YoY to RMB 1.53 billion in the first six months of 2022.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced that it has signed an agreement to acquire Positron Precision GmbH, a company developing a technology platform for positron emission tomography tracers and various radiotherapeutic candidates.